HCFA Reimbursement For Epogen, Takeover Talk Help Amgen Grow In June
A second increase in the Health Care Financing Administration reimbursement rates for Epogen has aided in increasing the valuation of Amgen in the financial community
You may also be interested in...
Medicare claims for use of Amgen's Aranesp and Epogen in end-stage renal disease will be monitored through blood hematocrit or hemoglobin levels as well as dosage levels, a Centers for Medicare & Medicaid Services' draft policy says
Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.